Stockscreener 앱 받기
104.57
0.25%
-0.26
시간 외 거래:
105.33
0.76
+0.73%
전일 마감가:
$104.83
열려 있는:
$104.39
하루 거래량:
5.98M
Relative Volume:
0.56
시가총액:
$181.71B
수익:
$44.33B
순이익/손실:
$6.50B
주가수익비율:
28.13
EPS:
3.717
순현금흐름:
$7.40B
1주 성능:
-2.44%
1개월 성능:
-10.06%
6개월 성능:
-21.70%
1년 성능:
-17.41%
1일 변동 폭
$104.00
$105.98
1주일 범위
$102.41
$107.79
52주 변동 폭
$102.41
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
104.57 | 182.16B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.68 | 125.39B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.67 | 112.84B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
70.17 | 103.71B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.10 | 48.01B | 6.07B | 1.06B | 1.34B | 1.8063 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Unit Beats Ex-Worker's Whistleblower Suit At 8th Circ. - Law360
Vanguard disaggregates holdings; ABT shows 0 shares (ABT) - Stock Titan
Abbott Labs Worker’s Wrongful Termination Suit Fails on Appeal - Bloomberg Law News
What Abbott Laboratories (ABT)'s Cancer Screening Deal and Libre Data Reveal About Its Chronic Care Ambitions - simplywall.st
Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences - Yahoo Finance
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott hosts conference call for first-quarter earnings - Abbott MediaRoom
Abbott will report first-quarter results before markets open April 16 - Stock Titan
Abbott Laboratories stock faces pipeline scrutiny amid diagnostics slowdown in Q1 2026 - AD HOC NEWS
Abbott (NYSE: ABT) SVP receives 13,255-share restricted stock award - Stock Titan
[Form 3] ABBOTT LABORATORIES Initial Sta... - Stock Titan
Mom Tying Abbott Formula To Baby's NEC Takes The Stand - Law360
Why Abbott (ABT) Is Betting $23B on Cancer Screening - MarketWise
Abbott Earnings Preview: What to Expect - Barchart
Abbott Laboratories Stock Hits Day Low of $105.40 Amid Price Pressure - Markets Mojo
Abbott Laboratories stock faces pressure amid diagnostics slowdown and FreeStyle Libre competition i - AD HOC NEWS
Is It Time To Reconsider Abbott Laboratories (ABT) After Recent Share Price Weakness? - Yahoo Finance
Abbott Proclaim SCS Lawsuit Alleges Stimulator Lead Migration Resulted in Multiple Surgeries - AboutLawsuits.com
Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover - Blockonomi
Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition - CoinCentral
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics - Citeline News & Insights
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance Singapore
Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results - Insider Monkey
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. - The Motley Fool
Abbott closes $23 billion deal to buy Madison-based Exact Sciences - Milwaukee Journal Sentinel
SG Americas Securities LLC Sells 102,478 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Labs completes acquisition of Madison’s Exact Sciences for $23 billion - Wisconsin State Journal
Nordea Investment Management AB Has $73.97 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories raised prices, prompting sales slump - MSN
E. Ohman J or Asset Management AB Invests $7.72 Million in Abbott Laboratories $ABT - MarketBeat
Dynamic Advisor Solutions LLC Sells 15,282 Shares of Abbott Laboratories $ABT - MarketBeat
Avanza Fonder AB Boosts Stock Position in Abbott Laboratories $ABT - MarketBeat
Assenagon Asset Management S.A. Increases Position in Abbott Laboratories $ABT - MarketBeat
U.S. Medical Nutrition Market Is Going to Boom | Abbott Laboratories • Nestlé Health Science • Danone - openPR.com
Abbott Laboratories stock completes $21 billion Exact Sciences acquisition, eyes diagnostics growth - AD HOC NEWS
Abbott completes acquisition of Exact Sciences - Abbott MediaRoom
Abbott Completes Exact Sciences Acquisition to Transform Global Cancer Diagnostics - geneonline.com
Abbott Expands Healthcare Ecosystem With Exact Sciences Acquisition - Built In Chicago
Exact Sciences Corp stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott finalizes purchase of Madison-based Exact Sciences - Spectrum News
Abbott closes $21B Exact Sciences deal - Crain's Chicago Business
Abbott Acquires Exact Sciences to Lead Cancer Screening and Diagnostics Market - Minichart
Abbott completes acquisition of Exact Sciences By Investing.com - Investing.com India
Abbott Laboratories (ABT) Completes Acquisition of Exact Sciences - GuruFocus
Abbott Laboratories stock hits 52-week low at 105.24 USD By Investing.com - Investing.com Canada
Abbott Laboratories stock hits 52-week low at 105.24 USD - Investing.com
Abbott (ABT) Acquires Exact Sciences to Expand Cancer Diagnostics Reach - GuruFocus
Abbott completes $21 billion acquisition of Exact Sciences, delisting EXAS from Nasdaq - Investing.com
Abbott Finalizes Exact Sciences Acquisition, Expands Cancer Diagnostics - TipRanks
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening - Intellectia AI
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
0.25%
자본화:
|
볼륨(24시간):